RT Journal Article
T1 Mesoangioblasts at 20: From the embryonic aorta to the patient bed
A1 Cossu, Giulio
A1 Tonlorenzi, Rossana
A1 Brunelli, Silvia
A1 Sampaolesi, Maurilio
A1 Messina, Graziella
A1 Azzoni, Emanuele
A1 Benedetti, Sara
A1 Biressi, Stefano
A1 Bonfanti, Chiara
A1 Bragg, Laricia
A1 Camps, Jordi
A1 Cappellari, Ornella
A1 Cassano, Marco
A1 Ciceri, Fabio
A1 Coletta, Marcello
A1 Covarello, Diego
A1 Crippa, Stefania
A1 Cusella-De Angelis, M. Gabriella
A1 Angelis, Luciana De
A1 Dellavalle, Arianna
A1 Diaz-Manera, Jordi
A1 Galli, Daniela
A1 Galli, Francesco
A1 Gargioli, Cesare
A1 Gerli, Mattia F. M.
A1 Giacomazzi, Giorgia
A1 González Gálvez, Beatriz
A1 Hoshiya, Hidetoshi
A1 Guttinger, Maria
A1 Innocenzi, Anna
A1 Minasi, M. Giulia
A1 Perani, Laura
A1 Previtali, Stefano C
A1 Quattrocelli, Mattia
A1 Ragazzi, Martina
A1 Roostalu, Urmas
A1 Rossi, Giuliana
A1 Scardigli, Raffaella
A1 Sirabella, Dario
A1 Saverio Tedesco, Francesco
A1 Torrente, Yvan
A1 Ugarte, Gonzalo
A2 Feng Yue, 
AB In 2002 we published an article describing a population of vessel-associated progenitors that we termed mesoangioblasts (MABs). During the past decade evidence had accumulated that during muscle development and regeneration things may be more complex than a simple sequence of binary choices (e.g., dorsal vs. ventral somite). LacZ expressing fibroblasts could fuse with unlabelled myoblasts but not among themselves or with other cell types. Bone marrow derived, circulating progenitors were able to participate in muscle regeneration, though in very small percentage. Searching for the embryonic origin of these progenitors, we identified them as originating at least in part from the embryonic aorta and, at later stages, from the microvasculature of skeletal muscle. While continuing to investigate origin and fate of MABs, the fact that they could be expanded in vitro (also from human muscle) and cross the vessel wall, suggested a protocol for the cell therapy of muscular dystrophies. We tested this protocol in mice and dogs before proceeding to the first clinical trial on Duchenne Muscular Dystrophy patients that showed safety but minimal efficacy. In the last years, we have worked to overcome the problem of low engraftment and tried to understand their role as auxiliary myogenic progenitors during development and regeneration.
SN 1664-8021
YR 2023
FD 2023-01-04
LK https://hdl.handle.net/20.500.14352/104680
UL https://hdl.handle.net/20.500.14352/104680
LA eng
NO Cossu G, Tonlorenzi R, Brunelli S, Sampaolesi M, Messina G, Azzoni E, Benedetti S, Biressi S, Bonfanti C, Bragg L, Camps J, Cappellari O, Cassano M, Ciceri F, Coletta M, Covarello D, Crippa S, Cusella-De Angelis MG, De Angelis L, Dellavalle A, Diaz-Manera J, Galli D, Galli F, Gargioli C, Gerli MFM, Giacomazzi G, Galvez BG, Hoshiya H, Guttinger M, Innocenzi A, Minasi MG, Perani L, Previtali SC, Quattrocelli M, Ragazzi M, Roostalu U, Rossi G, Scardigli R, Sirabella D, Tedesco FS, Torrente Y and Ugarte G (2023), Mesoangioblasts at 20: From the embryonic aorta to the patient bed. Front. Genet. 13:1056114. doi: 10.3389/fgene.2022.1056114
DS Docta Complutense
RD 19 dic 2025